Few specialties challenge the buy-and-bill model the way oncology does. Infused and injectable therapies flow through hospitals, clinics, and physician offices that purchase the drug, administer it, and bill the payer for both the drug and the administration service. This is the most common model for provider-administered drugs such as injectables and infused therapies, especially in oncology and rheumatology.
Because the drug moves through the provider rather than a specialty pharmacy, buy and bill brands often have limited specialty pharmacy data. But limited data should never mean limited visibility.
What Buy and Bill Actually Means
Providers take on financial risk by purchasing drugs upfront and waiting for reimbursement, which may not always cover costs if claims are denied or delayed. Providers can also mark up the price of drugs, creating a potential revenue stream, but this comes with administrative burdens and inventory risk. Partly for these reasons, the model is becoming less common as payers shift to other models to control costs.
Compare that to brown bagging, where the patient obtains the medication from a specialty pharmacy and brings it to the provider for administration, or white bagging, where the specialty pharmacy ships the medication directly to the provider. In both of those models, the provider bills only for administration, not the drug itself.
Why This Hits Oncology Harder
The channel is genuinely more fragmented. Buy and bill manufacturers need visibility across specialty distributors, GPOs, and 3PLs, in addition to hub, copay, and other third-party data such as IOD, IDN, and GPO sources.
The absence of a specialty pharmacy doesn’t remove the need for coordination. Even without an SP network, care coordination is still required between FRMs, providers, and the hub to resolve patient cases.
Many manufacturers assume they can manage this data on their own. Manufacturers of buy and bill drugs often assume they can manage all first-party, patient-level data themselves, without needing a third party to handle protected health information. While that’s technically feasible, the real question isn’t about their ability to integrate the data. It’s whether they have the tools and expertise to derive meaningful insights and drive better patient outcomes.
Visibility Across the Full Patient Journey
Claritas Rx provides visibility at every stage of the buy and bill treatment journey: diagnosis and prescribing, prior authorization, drug acquisition, scheduling and administration, billing and reimbursement, and ongoing patient support.
How Claritas Rx Supports Buy and Bill Oncology Brands
At Claritas Rx, we transform complex data into meaningful insights, delivering actionable intelligence and expert guidance that empower teams to drive better patient outcomes. Our support for buy and bill brands centers on three core capabilities:
Foundational Data Aggregation. We aggregate channel data from specialty distributors, GPOs, and 3PLs through our Trade and Contract Ops module, and compile hub, copay, and other third-party data, including IOD, IDN, and GPO sources.
Consent Clearinghouse™ standardizes and centralizes patient consent across oncology, rare disease, and specialty biopharma. It verifies, reconciles, and continuously monitors consent across every connected data source and network partner, giving manufacturers real-time visibility and a defensible compliance record.
Patient Watchtower™. Patient Watchtower helps teams see more of the patient journey and coordinate care with FRMs, providers, and the hub. It leverages AI to predict prescription abandonment and discontinuation.
Patient Services Omnichannel CRM. This unifies patient-level data, field activities, and partner interactions into a single HIPAA-compliant system, using omnichannel tools like secure email, portals, and messaging to collaborate and resolve cases faster.
Claritas Rx empowers buy and bill brands with actionable insights and expert guidance, delivering visibility across the patient journey and drug lifecycle. By revealing ROI drivers, including acquisition cost, reimbursement success, and patient volume, our data and automation solutions boost profitability and brand performance.
Ready to see what complete visibility could look like for your buy and bill brand? Schedule a call with our team or visit our Buy and Bill Brands page to learn more.
